Study of Mirikizumab Injection Given Under the Skin in Healthy Adults Aged 18 to 65

What this Trial Is About

This research aims to evaluate the safety and tolerability of mirikizumab LY3074828 when given as a single injection compared to two separate injections under the skin in healthy adult volunteers aged 18 to 65 years. The study is conducted in a Phase 1 setting to understand how the body processes the drug through blood tests. The trial is sponsored by Eli Lilly and Company and includes healthy participants without significant medical conditions. Participants will receive mirikizumab administered subcutaneously in one of three experimental arms. The study is randomized and open-label, comparing different injection methods of the same drug. The treatment period is followed by monitoring to assess pharmacokinetics, including maximum concentration and drug exposure over time. Throughout approximately 15 weeks, volunteers will undergo medical evaluations such as physical exams, laboratory tests, ECGs, and vital sign monitoring. Blood samples will be collected to measure drug levels and how the body absorbs and eliminates the study medication. Safety and tolerability assessments will continue during this period to ensure participant well-being.

A Study of Mirikizumab Solution (LY3074828) in Healthy Participants